<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03603184</url>
  </required_header>
  <id_info>
    <org_study_id>IRFMN-EN-7556</org_study_id>
    <nct_id>NCT03603184</nct_id>
  </id_info>
  <brief_title>Atezolizumab Trial in Endometrial Cancer - AtTEnd</brief_title>
  <acronym>AtTEnd</acronym>
  <official_title>Phase III Double-blind Randomized Placebo Controlled Trial of Atezolizumab in Combination With Paclitaxel and Carboplatin in Women With Advanced/Recurrent Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mario Negri Institute for Pharmacological Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mario Negri Institute for Pharmacological Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atezolizumab is an engineered humanised monoclonal immunoglobulin G1 antibody that binds
      selectively to PD-L1 and prevents its interaction with PD-1 and B7-1.

      In May 2016 atezolizumab was approved by the FDA for patients with locally advanced or
      metastatic urothelial carcinoma who have disease progression during or following any
      platinum-containing chemotherapy, or within 12 months of receiving chemotherapy before
      surgery (neoadjuvant) or after surgery (adjuvant); in October 2016 it was approved by the FDA
      for patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression
      during or following platinum-containing chemotherapy, and have progressed on an appropriate
      FDA-approved targeted therapy if their tumor has EGFR or ALK gene abnormalities. Finally, in
      April 2017 atezolizumab was granted accelerated approval by FDA for the first-line treatment
      of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for
      cisplatin chemotherapy. Combinations of atezolizumab with chemotherapeutic agents and/or
      targeted therapies were studied in different solid tumors such as melanoma, NSCLC, renal cell
      carcinoma and colorectal carcinoma. From these studies the AE profile of atezolizumab
      combinations were consistent with that of the individual agents.

      Finally, preliminary results of a Phase Ia study of Atezolizumab (NCT01375842) monotherapy in
      relapsed endometrial cancer were reported as abstract at ASCO 2017. Fifteen patients were
      evaluated for safety and efficacy with a minimum follow-up of 11.2 months. No G4-5 related
      AEs occurred. Regarding efficacy ORR was 13% [2/15] by RECIST. Atezolizumab seemed to have a
      favorable safety profile, with durable clinical benefit in some patients. Further studies
      with atezolizumab are warranted given its promising results in advanced endometrial cancer
      and the limited efficacy of current treatment options.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2, 2018</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>OS</measure>
    <time_frame>Up to two years after the last patient enrolled</time_frame>
    <description>OS is defined as the time from randomization until the date of death from any cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>Up to two years after the last patient enrolled</time_frame>
    <description>PFS is defined as the time from randomization to the date of first progression or death from any cause, whichever comes first.
Progression will be established as the radiological disease progression according to RECIST 1.1 or death from any cause, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Up to two years after the last patient enrolled</time_frame>
    <description>Objective Response Rate (ORR), defined as the percentage of patients with an objective response as determined by RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to two years after the last patient enrolled</time_frame>
    <description>Duration of response, defined as the time from the date of first documentation of response (complete response (CR) or partial response (PR), whichever occurs first) to the date of documented PD or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Maximum toxicity grade</measure>
    <time_frame>Up to 30 days after the end of treatment</time_frame>
    <description>Maximum toxicity grade experienced by each patient, for each toxicity, according to NCI-CTCAE v. 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Number of patients experiencing grade 3-4 toxicity for each toxicity</measure>
    <time_frame>Up to 30 days after the end of treatment</time_frame>
    <description>Number of patients experiencing grade 3-4 toxicity for each toxicity according to NCI-CTCAE v. 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Type, frequency and nature of SAEs</measure>
    <time_frame>Up to 30 days after the end of treatment</time_frame>
    <description>Type, frequency and nature of SAEs, according to NCI-CTCAE v. 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Number of patients with at least a SAE</measure>
    <time_frame>Up to 30 days after the end of treatment</time_frame>
    <description>Number of patients with at least a SAE according to NCI-CTCAE v. 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Number of patients with at least a SADR</measure>
    <time_frame>Up to two years after the last patient enrolled</time_frame>
    <description>Number of patients with at least a SADR, according to NCI-CTCAE v. 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Number of patients with at least a SUSAR</measure>
    <time_frame>Up to two years after the last patient enrolled</time_frame>
    <description>Number of patients with at least a SUSAR, according to NCI-CTCAE v. 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life: EORTC QLQ-C30 questionnaire</measure>
    <time_frame>Up to two years after the last patient enrolled</time_frame>
    <description>Mean changes from the baseline scores in quality of life by cycle and between treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life: QLQ-EN24 questionnaire</measure>
    <time_frame>Up to two years after the last patient enrolled</time_frame>
    <description>Mean changes from the baseline score in quality of life by cycle and between treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life: GP5 item</measure>
    <time_frame>Up to two years after the last patient enrolled</time_frame>
    <description>Proportion of patients reporting each response option at each assessment timepoint by treatment arm for item GP5 from the FACT G instrument.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance: Number of administered cycles</measure>
    <time_frame>Up to two year after the last patient enrolled</time_frame>
    <description>Number of administered cycles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance: Reasons for discontinuation and treatment modification</measure>
    <time_frame>Up to two year after the last patient enrolled</time_frame>
    <description>Number of patients for each reasons</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance: Dose intensity</measure>
    <time_frame>Up to two year after the last patient enrolled</time_frame>
    <description>Entire dose administered during treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">550</enrollment>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>paclitaxel 175 mg/m2 + carboplatin AUC 5 or 6 will be administered every 21 days for 6-8 cycles or PD. Atezolizumab will be administered as I.V. infusion at a fixed dose of 1200 mg, every 21 days until objective radiological disease progression as assessed by the investigator if they do not meet any other discontinuation criteria (patient refusal, toxicity). Patients who are clinically stable at initial RECIST v 1.1 - defined progression - should continue on treatment until the next imaging assessment that should be ≥4 weeks and no longer than 8 weeks later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>paclitaxel 175 mg/m2 + carboplatin AUC 5 or AUC 6 will be administered every 21 days for 6-8 cycles or PD. Placebo will be administered as I.V. infusion every 21 days until objective radiological disease progression as assessed by the investigator if they do not meet any other discontinuation criteria (patient refusal, toxicity). Patients who are clinically stable at initial RECIST v 1.1 - defined progression - should continue on treatment until the next imaging assessment that should be ≥4 weeks and no longer than 8 weeks later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Atezolizumab will be administered as I.V. infusion at a fixed dose of 1200 mg, every 21 days until objective radiological disease progression as assessed by the investigator if they do not meet any other discontinuation criteria (patient refusal, toxicity).</description>
    <arm_group_label>Experimental arm</arm_group_label>
    <other_name>Tecentriq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo will be administered as I.V. infusion every 21 days until objective radiological disease progression as assessed by the investigator if they do not meet any other discontinuation criteria (patient refusal, toxicity).</description>
    <arm_group_label>Control arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel 175 mg/m2 will be administered every 21 days for 6-8 cycles or until progression of disease.</description>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin AUC 5 or AUC 6 will be administered every 21 days for 6-8 cycles or until progression of disease.</description>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        I-1. Newly diagnosed, histologically-confirmed with residual disease after surgery either
        measurable or evaluable, or inoperable stage III-IV endometrial carcinoma/carcinosarcoma,
        after diagnostic biopsy, and naïve to first line systemic anti-cancer treatment. Recurrent
        endometrial cancer patients if not yet treated for recurrent disease.

        I-2. Eastern Cooperative Oncology Group (ECOG) performance status 0-2 I-3. Age ≥ 18 years
        I-4. Only one prior line of systemic platinum-based regimen is permitted if the
        platinum-free interval ≥ 6 months. Such prior line is the up-front/adjuvant treatment which
        can be concurrent chemoradiation or concurrent chemoradiation followed by chemotherapy or
        only chemotherapy.

        I-5. Patients with history of primary breast cancer may be eligible provided they completed
        their definitive anticancer treatment more than 3 years ago and they remain breast cancer
        disease free prior to start of study treatment.

        I-6. Previous pelvic and outside pelvis radiation is allowed if completed more than 6 weeks
        ago.

        I-7. Signed informed consent and ability to comply with treatment and follow-up.

        I-8. Representative FFPE tumor sample or, only if unfeasible, at least 20 unstained slides
        from initial surgery or from diagnostic biopsy, in case surgery was not performed,
        available and sent to central laboratory for Micro Satellite (MS) determination prior to
        randomization.

        I-9. Patients must have normal organ and bone marrow function :

          1. Haemoglobin ≥ 10.0 g/dL.

          2. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L.

          3. Platelet count ≥ 100 x 109/L.

          4. Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN).

          5. Aspartate aminotransferase /Serum Glutamic Oxaloacetic Transaminase (ASAT/SGOT)) and
             Alanine aminotransferase /Serum Glutamic Pyruvate Transaminase (ALAT/SGPT)) ≤ 2.5 x
             ULN, unless liver metastases are present in which case they must be ≤ 5 x ULN.

          6. Serum creatinine ≤ 1.5 x institutional ULN

        Exclusion Criteria:

        E-1. Other malignancy within the last 5 years except: adequately treated non-melanoma skin
        cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS) of
        the breast. Patients with a history of localized malignancy diagnosed over 5 years ago may
        be eligible provided they completed their adjuvant systemic therapy prior to randomization
        and that the patient remains free of recurrent or metastatic disease.

        E-2. Patients with uterine leiomyosarcoma . E-3. Major surgery within 4 weeks of starting
        study treatment or patients who have not completely recovered from the effects of any major
        surgery.

        E-4. Previous allogeneic bone marrow transplant or previous solid organ transplantation.

        E-5. Administration of other simultaneous chemotherapy drugs, any other anticancer therapy
        or anti-neoplastic hormonal therapy, or simultaneous radiotherapy during the trial
        treatment period (hormonal replacement therapy is permitted).

        E-6. Prior treatment with CD137 agonists or immune checkpoint blockade therapies, anti−PD1,
        or anti−PDL1 therapeutic antibodies or anti-CTLA4 .

        E-7. Treatment with systemic immunostimulatory agents (including but not limited to
        interferon-alpha (IFN-α) and interleukin-2 (IL-2) within 4 weeks or five half-lives of the
        drug (whichever is shorter) prior to Cycle 1, Day 1.

        E-8. Treatment with systemic corticosteroids or other systemic immunosuppressive
        medications (including but not limited to prednisone, dexamethasone, cyclophosphamide,
        azathioprine, methotrexate, thalidomide, and anti−tumor necrosis factor [TNF] agents)
        within 2 weeks prior to Cycle 1, Day 1, or anticipated requirement for systemic
        immunosuppressive medications during the trial. However, please note that the use of
        inhaled corticosteroids for chronic obstructive pulmonary disease or for asthma is allowed,
        as well as the use of mineralocorticoids (e.g., fludrocortisones) and low-dose supplemental
        corticosteroids for adrenocortical insufficiency and for patients with orthostatic
        hypotension. The use of corticosteroids as premedication for paclitaxel-based regimen is
        allowed).

        E-9. History of autoimmune disease, including but not limited to myasthenia gravis,
        myositis,autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis,
        inflammatory bowel disease, vascular thrombosis associated with anti-phospholipid syndrome,
        Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis,
        vasculitis, or glomerulonephritis [please note: patients with a history of autoimmune
        hypothyroidism on a stable dose of thyroid replacement hormone are eligible; patients with
        controlled Type 1 diabetes mellitus on a stable insulin regimen are eligible; history of
        idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing
        pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia) is permitted].

        E-10. Immunocompromised patients, e.g., patients who are known to be serologically positive
        for human immunodeficiency virus (HIV).

        E-11. Patients with active hepatitis B (defined as having a positive hepatitis B surface
        antigen [HBsAg] test at screening) or hepatitis C .

          1. Patients with past hepatitis B virus (HBV) infection or resolved HBV infection
             (defined as having a negative HBsAg test and a positive total hepatitis B core
             antibody [HBcAb]) are eligible only if hepatitis B virus (HBV) DNA is negative. The
             HBV DNA test will be performed only for patients who have a positive total HBcAb test.

          2. Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase
             chain reaction (PCR) is negative for HCV RNA. The HCV RNA test will be performed only
             for patients who have a positive HCV antibody test.

        E-12. Active tuberculosis (all patients will have tuberculin [PPD] skin test or
        Interferon-Gamma Releasing Assay [IGRA] done locally prior to inclusion to study) E-13.
        Signs or symptoms of infection within 2 weeks prior to Cycle 1, Day 1 E-14. Administration
        of a live, attenuated vaccine within 4 weeks prior to Cycle 1, Day 1 or anticipation that
        such a live attenuated vaccine will be required during the study. Influenza vaccination
        should be given during influenza season only (example approximately October to March in the
        Northern Hemisphere). Patients must not receive live, attenuated influenza vaccine.

        E-15. Clinically significant (e.g. active) cardiovascular disease, including:

          1. Myocardial infarction or unstable angina within ≤ 6 months of randomization,

          2. New York Heart Association (NYHA) ≥ grade 2 congestive heart failure (CHF),

          3. Poorly controlled cardiac arrhythmia despite medication (patients with rate controlled
             atrial fibrillation are eligible),

          4. Peripheral vascular disease grade ≥ 3 (e.g. symptomatic and interfering with
             activities of daily living [ADL] requiring repair or revision) E-16. Resting ECG with
             QTc &gt; 470 msec on 2 or more time points within a 24 hour period or family history of
             long QT syndrome.

        E-17. History or clinical suspicion of brain metastases or spinal cord compression. CT/MRI
        of the brain is mandatory (within 4 weeks prior to randomization) in case of suspected
        brain metastases. Spinal MRI is mandatory (within 4 weeks prior to randomization) in any
        case of suspected central nervous system (CNS) involvement .

        E-18. History or evidence upon neurological examination of central nervous system (CNS)
        disease, unless asymptomatic and adequately treated with standard medical therapy.

        E-19. Evidence of any other disease, metabolic dysfunction, physical examination finding or
        laboratory finding giving reasonable suspicion of a disease or condition that
        contraindicates the use of an investigational drug or puts the patient at high risk for
        treatment related complications.

        E-20. Women of childbearing potential (&lt;2 years after last menstruation) not willing to use
        highly-effective means of contraception.

        E-21. Pregnant or lactating women. E-22. History of severe allergic, anaphylactic, or other
        hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.

        E-23. Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster
        ovary cells or to any component of the atezolizumab formulation.

        E-24. Known hypersensitivity reaction or allergy to drugs chemically related to
        carboplatin, paclitaxel, or their excipients that contraindicates the subject's
        participation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicoletta Colombo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Europeo di Oncologia (IEO) - Milan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elena Biagioli</last_name>
    <phone>+390239014650</phone>
    <email>attend@marionegri.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roldano Fossati</last_name>
    <email>attend@marionegri.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medizinische Universitaet Graz - Universitätsklinik für Frauenheilkunde und Geburtshilfe</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edgar Petru</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Marth</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Braicu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen Mitte</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beyhan Ataseven</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UniversitätsKlinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederik Marmé</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Ludwig-Maximilians-Universität München (LMU)</name>
      <address>
        <city>Muenchen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabian Trillsch</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AO SS Antonio e Biagio e Cesare Arrigo</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vittorio Fusco</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico S. Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio Zamagni</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria dell'Alto Adige</name>
      <address>
        <city>Bolzano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria R Lusso</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST degli Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Germana Tognon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione Poliambulanza</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chiara Abeni</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Cagliari, Policlinico Universitario</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Massa</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Sant Anna di Como</name>
      <address>
        <city>Como</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Monica Giordano</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Careggi</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lorenzo Antonuzzo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ente ospedaliero Ospedali Galliera</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea De Censi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST di Lecco</name>
      <address>
        <city>Lecco</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Ardizzoia</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Luca</name>
      <address>
        <city>Lucca</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Editta Baldini</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicoletta Colombo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea A Lissoni</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto (IOV)</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giulia Tasca</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU di Parma</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonino Musolino</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Pisana</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angiolo Gadducci</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AO Arcispedale Santa Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra Bologna</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ausl Romagna</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Valentina Arcangeli</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I, Università di Roma &quot;La Sapienza&quot;</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierluigi Benedetti Panici</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale di Sondrio ASST Valtellina e Alto Lario</name>
      <address>
        <city>Sondrio</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Bertolini</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale SS Trinità</name>
      <address>
        <city>Sora</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filomena Narducci</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AO Ordine Mauriziano</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annamaria Ferrero</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Città della Salute e della Scienza di Torino - Ospedale Sant'Anna</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Zola</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale del Ponte di Varese</name>
      <address>
        <city>Varese</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicoletta Donadello</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>P.O Sant'Andrea Vercelli</name>
      <address>
        <city>Vercelli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elvira De Marino</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hirosaki University Hospital</name>
      <address>
        <city>Aomori</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoshihito Yokoyama</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenichi Harano</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shikoku Cancer Center</name>
      <address>
        <city>Ehime</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kazuhiro Takehara</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kurume University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shin Nishio</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hidemichi Watari</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hideki Tokunaga</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Niigata University Medical＆Dental Hospital</name>
      <address>
        <city>Niigata</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takayuki Enomoto</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Satoshi Nakagawa</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shizuoka Cancer Center</name>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nobutaka Takahashi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Keio University Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daisuke Aoki</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital De Sant Pau I La Santa Creu</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Martin Lorente</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d´Hebron Institute of Oncology (VHIO)</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Mazaltob Oaknin Benzaquen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Català d'Oncologia (ICO) Girona</name>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pilar Barretina</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Català d'Oncologia (ICO), L'Hospitalet- Hospital Duran I Reynals</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Gil Martin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Manso</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrés Redondo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raul Marquez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Palacio</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Santiago de Compostela</name>
      <address>
        <city>Santiago De Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Cueva</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet Zaragoza</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Herrero</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital</name>
      <address>
        <city>Baden</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Heubner</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsspital</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viola Heinzelmann</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inselspital</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuela Rabaglio</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital</name>
      <address>
        <city>Luzern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Aebi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Frauenfeld</name>
      <address>
        <city>Thurgau</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Fehr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IOSI</name>
      <address>
        <city>Ticino</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria del Grande</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital</name>
      <address>
        <city>Winterthur</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andreas Müller</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsspital</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Samartzis Eleftherios</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal United Hospital Bath</name>
      <address>
        <city>Avon</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emma de Winton</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Betsi Cadwaladr University Health Board</name>
      <address>
        <city>Bangor</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna Mullard</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Cancer Centre</name>
      <address>
        <city>Bebington</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rosemary Lord</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital Birmingham</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarah Williams</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Derby Hospital</name>
      <address>
        <city>Derby</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mojca Persic</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Devon &amp; Exeter Hospital</name>
      <address>
        <city>Exeter</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jenny Forrest</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre, Gartnavel General Hospital</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Azmat Sadozye</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Velindre Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emma Hudson</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gloucestershire Hospital NHS Foundation Trust</name>
      <address>
        <city>Gloucester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Audrey Cook</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guy's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna Winship</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laura Tookman</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexandra Taylor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Melaine Powell</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Kent Oncology Centre</name>
      <address>
        <city>Maidstone</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christos Mikropoulos</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrew Clamp</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northampton General Hospital</name>
      <address>
        <city>Northampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roshan Agarwal</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NUHT - Nottingham University Hospital NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anjana Anand</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sidharth Dubey</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Berkshire NHS Foundation Trust</name>
      <address>
        <city>Reading</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Helen O'Donnell</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vicky McFarlane</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Univerisity Hospitals of North Midlands NHS Trust</name>
      <address>
        <city>Stoke-on-Trent</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rajanee Bhana</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>South West Wales Cancer Institute Singleton Hospital</name>
      <address>
        <city>Swansea</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rachel Jones</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Musgrove Park Hospital</name>
      <address>
        <city>Taunton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emma Cattell</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 21, 2018</study_first_submitted>
  <study_first_submitted_qc>July 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2018</study_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endometrial cancer</keyword>
  <keyword>neoplasm</keyword>
  <keyword>immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

